These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27567268)

  • 41. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
    Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
    Verheul R; Lehert P; Geerlings PJ; Koeter MW; van den Brink W
    Psychopharmacology (Berl); 2005 Mar; 178(2-3):167-73. PubMed ID: 15322728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Commentary on Subbaraman et al. (2013) [corrected]: cravings as a mediator and moderator of drinking outcomes in the COMBINE Study.
    Anton RF
    Addiction; 2013 Oct; 108(10):1745-6. PubMed ID: 24033779
    [No Abstract]   [Full Text] [Related]  

  • 45. How Much Is Too Much? Patterns of Drinking During Alcohol Treatment and Associations With Post-Treatment Outcomes Across Three Alcohol Clinical Trials.
    Witkiewitz K; Roos CR; Pearson MR; Hallgren KA; Maisto SA; Kirouac M; Forcehimes AA; Wilson AD; Robinson CS; McCallion E; Tonigan JS; Heather N
    J Stud Alcohol Drugs; 2017 Jan; 78(1):59-69. PubMed ID: 27936365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Goal commitment predicts treatment outcome for adolescents with alcohol use disorder.
    Kaminer Y; Ohannessian CM; McKay JR; Burke RH; Flannery K
    Addict Behav; 2018 Jan; 76():122-128. PubMed ID: 28800496
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.
    Mason BJ; Goodman AM; Chabac S; Lehert P
    J Psychiatr Res; 2006 Aug; 40(5):383-93. PubMed ID: 16546214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trajectories of drinking urges and the initiation of abstinence during cognitive-behavioral alcohol treatment.
    Hallgren KA; McCrady BS; Epstein EE
    Addiction; 2016 May; 111(5):854-65. PubMed ID: 26709608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review.
    Khan A; Tansel A; White DL; Kayani WT; Bano S; Lindsay J; El-Serag HB; Kanwal F
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):191-202.e1-4; quiz e20. PubMed ID: 26256464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive value of non-consumption outcome measures in alcohol use disorder treatment.
    Kirouac M; Witkiewitz K
    Addiction; 2019 Jun; 114(6):1086-1092. PubMed ID: 30650471
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence.
    García ML; Blasco-Algora S; Fernández-Rodríguez CM
    World J Gastroenterol; 2015 Jul; 21(28):8516-26. PubMed ID: 26229395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic factors of 2-year outcomes of patients with comorbid bipolar disorder or depression with alcohol dependence: importance of early abstinence.
    Farren CK; Snee L; Daly P; McElroy S
    Alcohol Alcohol; 2013; 48(1):93-8. PubMed ID: 23059424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differing patterns of stress and craving across the day in moderate-heavy alcohol consumers during their typical drinking routine and an imposed period of alcohol abstinence.
    Mayhugh RE; Rejeski WJ; Petrie MR; Laurienti PJ; Gauvin L
    PLoS One; 2018; 13(4):e0195063. PubMed ID: 29668736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
    Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
    Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
    O'Malley SS; Garbutt JC; Gastfriend DR; Dong Q; Kranzler HR
    J Clin Psychopharmacol; 2007 Oct; 27(5):507-12. PubMed ID: 17873686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using a randomized controlled trial to test whether modifications to contingency management improve outcomes for heavy drinkers with serious mental illness.
    Oluwoye O; Skalisky J; Burduli E; Chaytor NS; McPherson S; Murphy SM; Herron J; Hirchak K; Burley M; Ries RK; Roll JM; McDonell MG
    Contemp Clin Trials; 2018 Jun; 69():92-98. PubMed ID: 29680318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does acamprosate improve reduction of drinking as well as aiding abstinence?
    Chick J; Lehert P; Landron F;
    J Psychopharmacol; 2003 Dec; 17(4):397-402. PubMed ID: 14870951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autobiographical Memory Deficits in Alcohol-Dependent Patients with Short- and Long-Term Abstinence.
    Nandrino JL; El Haj M; Torre J; Naye D; Douchet H; Danel T; Cottençin O
    Alcohol Clin Exp Res; 2016 Apr; 40(4):865-73. PubMed ID: 26990362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Breathalyser-Based eHealth Data Suggest That Self-Reporting of Abstinence Is a Poor Outcome Measure for Alcohol Use Disorder Clinical Trials.
    Hämäläinen MD; Zetterström A; Winkvist M; Söderquist M; Öhagen P; Andersson K; Nyberg F
    Alcohol Alcohol; 2020 Apr; 55(3):237-245. PubMed ID: 32118260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.